Sevirumab
Modify Date: 2024-01-02 12:21:45
Sevirumab structure
|
Common Name | Sevirumab | ||
|---|---|---|---|---|
| CAS Number | 138660-96-5 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SevirumabSevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL[1][2]. |
| Name | Sevirumab |
|---|
| Description | Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL[1][2]. |
|---|---|
| Related Catalog | |
| Target |
EC50: 0.3 μg/mL (CMV)[1] |
| In Vitro | Sevirumab (MSL-109) 扰乱 gH/gL 同型二聚体，而不是取消二聚。Sevirumab 可以将二聚体在足够的距离上分开，以减少荧光共振能量转移 (FRET)，并最终阻止正常的 gH/gL 功能[2]。 |
| References |
| No Any Chemical & Physical Properties |